News
RGEN
144.46
-1.42%
-2.08
Repligen Price Target Announced at $165.00/Share by Canaccord Genuity
Dow Jones · 4d ago
Repligen Initiated at Hold by Canaccord Genuity
Dow Jones · 4d ago
Canaccord Genuity Initiates Coverage On Repligen with Hold Rating, Announces Price Target of $165
Benzinga · 4d ago
U.S. RESEARCH ROUNDUP-Domino's Pizza, Honeywell, Walmart
Reuters · 4d ago
REPLIGEN CORP <RGEN.O>: CANACCORD GENUITY INITIATES COVERAGE WITH HOLD RATING; TARGET PRICE $165
Reuters · 4d ago
Repligen initiated with a Hold at Canaccord
TipRanks · 5d ago
BIOLIFE SOLUTIONS APPOINTS TONY J. HUNT TO ITS BOARD OF DIRECTORS
Reuters · 5d ago
Press Release: BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
Dow Jones · 5d ago
Weekly Report: what happened at RGEN last week (1209-1213)?
Weekly Report · 5d ago
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
NASDAQ · 12/12 16:30
Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report
Barchart · 12/12 06:30
Allspring Premier Large Company Growth Fund Q3 2024 Commentary
Seeking Alpha · 12/11 12:55
BNY Mellon Small/Mid Cap Growth Fund Q3 2024 Commentary
Seeking Alpha · 12/10 10:03
Repligen Corporation Launches AVIPure® dsRNA Clear OPUS® Columns to Enhance mRNA Therapeutics Production
Barchart · 12/09 16:50
Repligen launches AVIPure dsRNA Clear OPUS columns
TipRanks · 12/09 13:46
Weekly Report: what happened at RGEN last week (1202-1206)?
Weekly Report · 12/09 09:10
Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns
Barchart · 12/09 06:30
Polen U.S. Small Company Growth Q3 2024 Commentary
Seeking Alpha · 12/04 03:50
Harding Loevner Global Developed Markets Equity Q3 2024 Report
Seeking Alpha · 12/03 16:45
Weekly Report: what happened at RGEN last week (1125-1129)?
Weekly Report · 12/02 09:10
More
Webull provides a variety of real-time RGEN stock news. You can receive the latest news about Repligen through multiple platforms. This information may help you make smarter investment decisions.
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.